Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short term Debt (2019 - 2022)

Historic Short term Debt for Theravance Biopharma (TBPH) over the last 4 years, with Q1 2022 value amounting to $9.0 million.

  • Theravance Biopharma's Short term Debt fell 2270.35% to $9.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $9.0 million, marking a year-over-year decrease of 2270.35%. This contributed to the annual value of $16.9 million for FY2021, which is 1238.23% down from last year.
  • Latest data reveals that Theravance Biopharma reported Short term Debt of $9.0 million as of Q1 2022, which was down 2270.35% from $16.9 million recorded in Q4 2021.
  • Theravance Biopharma's 5-year Short term Debt high stood at $19.3 million for Q4 2020, and its period low was $6.9 million during Q2 2021.
  • For the 4-year period, Theravance Biopharma's Short term Debt averaged around $11.6 million, with its median value being $10.8 million (2019).
  • As far as peak fluctuations go, Theravance Biopharma's Short term Debt soared by 9626.43% in 2020, and later plummeted by 2270.35% in 2022.
  • Theravance Biopharma's Short term Debt (Quarter) stood at $9.9 million in 2019, then soared by 96.26% to $19.3 million in 2020, then decreased by 12.38% to $16.9 million in 2021, then tumbled by 46.8% to $9.0 million in 2022.
  • Its Short term Debt stands at $9.0 million for Q1 2022, versus $16.9 million for Q4 2021 and $12.5 million for Q3 2021.